<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03684447</url>
  </required_header>
  <id_info>
    <org_study_id>00116093</org_study_id>
    <nct_id>NCT03684447</nct_id>
  </id_info>
  <brief_title>Neural and Antidepressant Effects of Propofol</brief_title>
  <official_title>Neural and Antidepressant Effects of Propofol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the antidepressant effects of propofol at two different doses while
      measuring potential treatment-related biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim 1: Compare the clinical antidepressant effects of high-dose versus low-dose propofol.

      Aim 2: Characterize the dose-dependent effects of propofol on brain function and gene
      expression
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2019</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale</measure>
    <time_frame>approximately 17 days after randomization</time_frame>
    <description>24-item Hamilton Depression Rating Scale, total score Higher values represent more severe depressive symptoms Maximum score, 76; minimum score, 0 Remission defined as total score &lt; 10 Response defined as decrease of total score from baseline of 50% or greater</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale</measure>
    <time_frame>approximately 36 days after randomization</time_frame>
    <description>24-item Hamilton Depression Rating Scale, total score Higher values represent more severe depressive symptoms Maximum score, 76; minimum score, 0 Remission defined as total score &lt; 10 Response defined as decrease of total score from baseline of 50% or greater</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>Propofol High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high propofol injectable, individually dosed, three times per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low propofol injectable, individually dosed, three times per week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Series of 6-12 treatments with propofol</description>
    <arm_group_label>Propofol High Dose</arm_group_label>
    <arm_group_label>Propofol Low Dose</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age 18-55 years Diagnosis of major depressive disorder or bipolar disorder Current
        moderate-to-severe depressive episode Episode duration more than 2 months and less than 5
        years Failure of at least 2 adequate antidepressant medication trials within the past 2
        years 16-item Quick Inventory of Depressive Symptomatology, self-rated (QIDS) &gt; 10 24-item
        Hamilton Depression Rating Scale (HDRS) &gt; 18

        Exclusion Criteria:

        Contraindication to propofol, egg lecithin, soybean oil, or other study drugs Lifetime
        history of a serious suicide attempt(Gvion and Levi-Belz, 2018) Recent suicidal
        behavior(past 3 months) Body mass index &gt; 40 kg/m2 Daily use of benzodiazepine, opioid, ACE
        inhibitor, or ARB medication Symptomatic coronary artery disease or heart failure Poorly
        controlled hypertension or diabetes Abnormal kidney or liver function Pregnant or breast
        feeding Traumatic brain injury or significant neurologic signs (past year) Substance use
        disorder, moderate-to-severe(past 3 months) Obsessive compulsive disorder (past month)
        Post-traumatic stress disorder (past month) Schizophrenia-spectrum disorder (lifetime)
        Neurocognitive disorder (past year) Personality disorder as a current focus of treatment
        ECT within the past 3months Inappropriate for ECT, or poor response to ECT within the past
        5 years Incompetent to provide consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian J Mickey, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire Larson</last_name>
    <phone>801-829-7382</phone>
    <email>claire.larson@utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea White, PhD</last_name>
    <phone>801-829-7382</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Neuropsychiatric Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Brian Mickey</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

